- Home
- GDTC vs ATRA Comparison
GDTC vs ATRA Comparison
Compare GDTC & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- ATRA
- Stock Information
- Founded
- GDTC 2018
- ATRA 2012
- Country
- GDTC Singapore
- ATRA United States
- Employees
- GDTC N/A
- ATRA N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDTC Health Care
- ATRA Health Care
- Exchange
- GDTC Nasdaq
- ATRA Nasdaq
- Market Cap
- GDTC 28.0M
- ATRA 32.4M
- IPO Year
- GDTC 2023
- ATRA 2014
- Fundamental
- Price
- GDTC $2.40
- ATRA $6.90
- Analyst Decision
- GDTC Buy
- ATRA Buy
- Analyst Count
- GDTC 1
- ATRA 5
- Target Price
- GDTC $5.00
- ATRA $17.75
- AVG Volume (30 Days)
- GDTC 32.5K
- ATRA 48.6K
- Earning Date
- GDTC 01-01-0001
- ATRA 05-08-2025
- Dividend Yield
- GDTC N/A
- ATRA N/A
- EPS Growth
- GDTC N/A
- ATRA N/A
- EPS
- GDTC N/A
- ATRA N/A
- Revenue
- GDTC $330,254.00
- ATRA $128,940,000.00
- Revenue This Year
- GDTC $14.71
- ATRA N/A
- Revenue Next Year
- GDTC N/A
- ATRA N/A
- P/E Ratio
- GDTC N/A
- ATRA N/A
- Revenue Growth
- GDTC N/A
- ATRA 1404.02
- 52 Week Low
- GDTC $1.20
- ATRA $5.01
- 52 Week High
- GDTC $4.05
- ATRA $19.00
- Technical
- Relative Strength Index (RSI)
- GDTC 48.41
- ATRA 57.45
- Support Level
- GDTC $2.20
- ATRA $5.62
- Resistance Level
- GDTC $2.46
- ATRA $6.11
- Average True Range (ATR)
- GDTC 0.21
- ATRA 0.59
- MACD
- GDTC 0.01
- ATRA 0.18
- Stochastic Oscillator
- GDTC 34.67
- ATRA 88.76
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).